TEVA.TA - Teva Pharmaceutical Industries Limited

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
8,421.00
-88.00 (-1.03%)
At close: 5:24PM IDT
Stock chart is not supported by your current browser
Previous Close8,509.00
Open8,509.00
Bid11,480.00 x 200
Ask5,898.00 x 34100
Day's Range8,421.00 - 8,583.00
52 Week Range3,820.00 - 11,850.00
Volume391,926
Avg. Volume626,299
Market Cap85.557B
Beta0.75
PE Ratio (TTM)N/A
EPS (TTM)-15.79
Earnings DateMay 9, 2018 - May 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-11-28
1y Target Est19.50
  • FDA Recalls Valsartan Drugs on Impurity Concerns: Teva Fell 1.8%
    Market Realist3 hours ago

    FDA Recalls Valsartan Drugs on Impurity Concerns: Teva Fell 1.8%

    On July 13, the FDA announced a voluntary recall of drugs containing valsartan and valsartan/hydrochlorothiazide API (active pharmaceutical ingredient) manufactured by Solco Healthcare, Major Pharmaceuticals, and Teva Pharmaceutical (TEVA). The drugs are used for the treatment of heart failure and high blood pressure.

  • Here's How Teva Pharmaceuticals Pulled Off a 28.3% Gain in the First Half of 2018
    Motley Fool18 hours ago

    Here's How Teva Pharmaceuticals Pulled Off a 28.3% Gain in the First Half of 2018

    Demand for generic drugs is on the rise, and investors are convinced the trend will keep this profitable company moving in the right direction.

  • 3 Warren Buffett Stocks Worth Buying Now
    Motley Fool3 days ago

    3 Warren Buffett Stocks Worth Buying Now

    These three stocks are backed by Buffett and Berkshire and could help power your portfolio to market-beating returns.

  • Has Teva Pharmaceutical Industries (TEVA) Outpaced Other Medical Stocks This Year?
    Zacks5 days ago

    Has Teva Pharmaceutical Industries (TEVA) Outpaced Other Medical Stocks This Year?

    Is (TEVA) Outperforming Other Medical Stocks This Year?

  • Business Wire5 days ago

    Teva to Report Second Quarter 2018 Financial Results on August 2, 2018

    Teva Pharmaceutical Industries Ltd. (TEVA) announced today that it will release its second quarter 2018 financial results on Thursday, August 2, 2018 at 7:00 a.m. ET. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its second quarter 2018 results and overall business environment.

  • Teva Announces Launch of Generic Version of Uceris in US
    Market Realist6 days ago

    Teva Announces Launch of Generic Version of Uceris in US

    On July 9, Teva announced the launch of its generic Uceris (budesonide) extended-release tablets (nine milligrams) in the United States. In November 2017, Teva prevailed in its litigation challenging Valeant Pharmaceuticals’ (VRX) Uceris patent, which was acquired through the acquisition of Salix in 2015. Teva was the first applicant to file an ANDA (abbreviated new drug application) for generic Uceris.

  • Associated Press7 days ago

    Correction: Teva-US-HQ Move story

    TRENTON, N.J. (AP) — In a story July 6 about Teva Pharmaceuticals moving its U.S. headquarters to New Jersey, The Associated Press erroneously reported the amount in tax credits the firm is receiving. The state's Economic Development authority approved about $40 million in credits over 10 years, not about $4 million in total credits over that period.

  • Business Wire7 days ago

    Teva Announces Launch of a Generic Version of Uceris® in the United States

    Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Uceris®1 (budesonide) extended-release tablets, 9 mg, in the U.S. Budesonide extended-release tablets are a glucocorticosteroid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. “The launch of generic budesonide extended-release tablets signals an important addition to Teva’s portfolio,” said Brendan O’Grady, EVP and head of North America Commercial.

  • TEVA or AKRX: Which Is the Better Value Stock Right Now?
    Zacks7 days ago

    TEVA or AKRX: Which Is the Better Value Stock Right Now?

    TEVA vs. AKRX: Which Stock Is the Better Value Option?

  • Can Teva’s Fremanezumab Revert Chronic Migraine to Episodic?
    Market Realist7 days ago

    Can Teva’s Fremanezumab Revert Chronic Migraine to Episodic?

    As we saw in the previous part of this series, Teva presented new data on fremanezumab at the AHS (American Headache Society) 60th Annual Scientific Meeting in San Francisco. It is one of Teva’s key pipeline drugs and is expected to be a key growth driver for the company. Teva’s specialty products pipeline is provided in the graph below.

  • Up in the air: Teva's 1M square feet of space in the suburbs
    American City Business Journals7 days ago

    Up in the air: Teva's 1M square feet of space in the suburbs

    Pennsylvania economic development officials weren't enticed to make a competing offer to keep Teva in the Philadelphia region, putting its presence in the suburbs in a precarious position.

  • Teva Presented New Data on Fremanezumab: What You Should Know
    Market Realist7 days ago

    Teva Presented New Data on Fremanezumab: What You Should Know

    During the AHS (American Headache Society) 60th Annual Scientific Meeting in San Francisco, which was held from June 28 to July 1, Teva presented new data on its much-awaited migraine drug fremanezumab. Teva has a September PDUFA (Prescription Drug User Fee Act) date for the drug. On June 15, the company provided an update on the drug’s Enforce Phase 3 clinical development program for cluster headaches.

  • Teva Pharmaceutical Stock in the Week Ended July 6
    Market Realist10 days ago

    Teva Pharmaceutical Stock in the Week Ended July 6

    On July 5, Teva Pharmaceutical Industries (TEVA) stock ended the trading day at $23.92, a fall of 3.2% compared to the previous day. TEVA stock was trading 121% higher than its 52-week low of $10.85 on November 2, 2017. Currently, Teva Pharmaceutical stock is trading higher than its 50-day moving average of $22.56 as well as its 200-day moving average of $19.85.

  • Analyst Recommendations for Teva Pharmaceutical in July
    Market Realist10 days ago

    Analyst Recommendations for Teva Pharmaceutical in July

    Teva Pharmaceutical Industries (TEVA) is one of the largest generic drug manufacturers. It has been recuperating from its recent troubles as it started facing generic competition for its key product Copaxone. Warren Buffet’s Berkshire Hathaway initiated investment in Teva in the previous quarter and increased it in the recently reported quarter.

  • Teva's decision to move North American HQ leaves other sites in jeopardy
    American City Business Journals10 days ago

    Teva's decision to move North American HQ leaves other sites in jeopardy

    Teva will relocate its North American headquarters to New Jersey, leaving questions about future of its operations in other states, including Kansas.

  • Teva moving North America headquarters from North Wales to North Jersey
    American City Business Journals11 days ago

    Teva moving North America headquarters from North Wales to North Jersey

    The generic drug manufacturer, which has about 2,000 employees in the Philadelphia suburbs, said it will continue to have a 'significant presence' in Pennsylvania.

  • Teva to Present New Data for Fremanezumab
    Market Realist18 days ago

    Teva to Present New Data for Fremanezumab

    Today, Teva Pharmaceutical Industries (TEVA) announced that it will present new data for its migraine drug Fremanezumab, which is under review by the FDA for the preventive treatment as a monthly or quarterly injection, at the AHS’s (American Headache Society) 60th Annual Scientific Meeting in San Francisco. The event is being held from June 28 to July 1. Teva plans to present 23 abstracts, three oral presentations, and one late-breaking poster of Fremanezumab.

  • Business Wire18 days ago

    Teva to Present New Fremanezumab Data, Including Long-Term Data, at the American Headache Society’s 60th Annual Scientific Meeting

    Teva Pharmaceutical Industries Ltd. today announced 23 abstracts, one late-breaking poster and three oral presentations of fremanezumab for the preventive treatment of migraine which will be presented at the American Headache Society’s 60th Annual Scientific Meeting in San Francisco from June 28-July 1, 2018.

  • 3 Best Big Pharma Stocks of 2018 So Far
    Motley Fool20 days ago

    3 Best Big Pharma Stocks of 2018 So Far

    Are any of these biggest year-to-date winners smart picks for the long term?

  • Analysts Raise Their 12-Month Target Price on Teva Pharmaceutical
    Market Realist27 days ago

    Analysts Raise Their 12-Month Target Price on Teva Pharmaceutical

    On June 11, Leerink raised its 12-month target price on Teva from $13 to $16 while maintaining its “underperform” rating on the stock. Leerink analyst Ami Fadia revised the target prices to better reflect the improving dynamics of the company.

  • Teva to Discontinue a Fremanezumab Study on Cluster Headache
    Zacks28 days ago

    Teva to Discontinue a Fremanezumab Study on Cluster Headache

    Teva decides to halt a phase III study, evaluating fremanezumab for the treatment of chronic cluster headache, following an interim analysis, which anticipates that the study is unlikely to meet its endpoint.

  • A Look at Teva’s Generic Drugs Research Pipeline
    Market Realist28 days ago

    A Look at Teva’s Generic Drugs Research Pipeline

    Teva Pharmaceutical Industries (TEVA) is the largest generics pharma manufacturer in the world. In particular, the FDA is approving generics versions of branded drugs more rapidly to shift toward a more affordable healthcare structure. Teva is on track to achieve targeted cost reductions and revenue growth.

  • Teva Scraps A Study In Cluster Headaches — And This Rival Benefits
    Investor's Business Dailylast month

    Teva Scraps A Study In Cluster Headaches — And This Rival Benefits

    Alder Biopharmaceuticals gapped up Friday after rival Teva Pharmaceutical scrapped a late-stage study in chronic cluster headaches.

  • Here's Why Alder Biopharmaceuticals Is Rising Today
    Motley Foollast month

    Here's Why Alder Biopharmaceuticals Is Rising Today

    Traders cheer after a rival drug maker decides to partially scrap a late-stage study. Here's what investors need to know.

  • Medial Devices & Teva. Plus, the bullish bet on this food...
    CNBC Videos19 days ago

    Medial Devices & Teva. Plus, the bullish bet on this food...

    Bernstein initiates coverage on health care names, with Intuitive Surgical, Boston Scientific, and Abbott Labs getting outperform ratings. Plus, BTIG upgrades Yum! Brands to buy, and Citi adds Teva Pharmaceutical to its "Focus List."